IR@PKUHSC  > 北京大学精神卫生研究所
学科主题精神卫生
Citalopram in the treatment of depressive disorders: an open label, multicenter study in China
Si, Tianmei; Shu, Liang
关键词Antidepressant Citalopram Depression Selective Serotonin Reuptake Inhibitor
刊名AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY
2008-05-01
2期:3页:59-65
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]SEROTONIN REUPTAKE INHIBITORS ; MAJOR DEPRESSION ; NEWER ANTIDEPRESSANTS ; DRUG-INTERACTIONS ; HUMAN CYTOCHROMES ; GENERAL-PRACTICE ; DOUBLE-BLIND ; PLACEBO ; THERAPY ; TRIAL
英文摘要

Results of randomized, placebo-controlled trials with the selective serotonin reuptake inhibitor citalopram suggest that this agent is safe and effective for the treatment of depressive disorders. We investigated the safety and efficacy of citalopram in the treatment of Chinese patients with depressive disorders. An 8-week, open-label, multicenter study evaluated the safety and efficacy of citalopram in the treatment of patients with an ICD-10 diagnosis of depressive disorder or depressive episode of bipolar disorder. Efficacy measures included the Hamilton Rating Scale for Depression (HAMD) and the Clinical Global Impression (CGI). A total of 6080 patients (2553 men, 3527 women) (mean age 40.9 +/- 15.6 years, range 18 - 92) participated in the study. Mean HAMD scores decreased significantly (p < 0.001) after 2 weeks of treatment and at all subsequent study visits. Endpoint analyses showed that 89.9% of the patients demonstrated a clinical response, defined as a >= 50% reduction in HAMD scores. The mean daily dose of citalopram at endpoint was 23.65 mg. Nausea (7.6%), headache (3.7%) and dry mouth (2.9%) were the most frequently reported adverse events. Patients with bipolar depression and comorbid obsessive compulsive disorder (OCD) received a higher mean daily dose (26.4 and 27.7 mg, respectively), while patients with comorbid physical disorders received a lower dose (21.9 mg) than patients with simple depressive disorder. The results of this 8-week open-label study suggest that citalopram is safe and effective in the treatment of depression in Chinese patients. Limitations is an open-label and uncontrolled.

语种英语
WOS记录号WOS:000262373300004
资助机构Wujieping Medical Science Foundation
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56637
专题北京大学精神卫生研究所
北京大学精神卫生研究所_药理室
作者单位Peking Univ, Inst Mental Hlth, Dept Clin Psychopharmacol, Beijing 100083, Peoples R China
推荐引用方式
GB/T 7714
Si, Tianmei,Shu, Liang. Citalopram in the treatment of depressive disorders: an open label, multicenter study in China[J]. AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY,2008,2(3):59-65.
APA Si, Tianmei,&Shu, Liang.(2008).Citalopram in the treatment of depressive disorders: an open label, multicenter study in China.AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY,2(3),59-65.
MLA Si, Tianmei,et al."Citalopram in the treatment of depressive disorders: an open label, multicenter study in China".AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY 2.3(2008):59-65.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Si, Tianmei]的文章
[Shu, Liang]的文章
百度学术
百度学术中相似的文章
[Si, Tianmei]的文章
[Shu, Liang]的文章
必应学术
必应学术中相似的文章
[Si, Tianmei]的文章
[Shu, Liang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。